s been with Weill Cornell Medicine/NYPH since 1992 when she began her fellowship in Endocrinology, Diabetes and Metabolism in the joint program with Memorial Sloan Kettering Cancer Center. Prior to that, she completed an internal medicine residency at Yale New Haven Hospital. She graduated from SUNY Buffalo School of Medicine and obt

Award Recipients: Consortium led by Angiocrine Scientific founder — Shahin Raffi, MD (Weill Cornell Medical) and collaborator Michel Sadelain, MD (Memorial Sloan Kettering Cancer Center) Weill Cornell Medical College Memorial Sloan Kettering Cancer Center,. • Disease Focus: Sickle Cell Anemia • Purpose: • Combine Angiocrine's E

ng access to certain prescribed targeted therapies. • Data release highlights: • In June, results from a new study conducted in partnership with Memorial Sloan Kettering Cancer Center (MSKCC) presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated that comprehensive genomic profiling of lung

h 13th with my company team to fight back and give to the ones in need. 100% of every dollar raised will fund pioneering rare cancer research led by Memorial Sloan Kettering Cancer Center. Rare cancer patients deserve new and better treatment options. A donation of any size ensures that more research gets funded, enabling new discove